TABLE 10.

Management of high TG.

Recommendation	Recommended classification	Evidence level
When TG > 5.6 mmol/L, treatment with fibrates, high-purity omega-3 fatty acids, or niacin may be used to reduce the risk of pancreatitis (Christian et al., 2012)	I	C
High-dose IPE (2 g twice daily) (Yokoyama et al., 2007; Bhatt et al., 2019) should be considered to reduce ASCVD risk in ASCVD patients and those at high risk of ASCVD who receive moderate doses of statins with TG > 2.3 mmol/L	IIa	B
ASCVD patients and those at high risk of ASCVD who receive moderate doses of statins with TG > 2.3 mmol/L may be given high-purity omega-3 fatty acids (Bhatt et al., 2019; O'Donoghue et al., 2022) or fenofibrate or benzofibrate to further reduce ASCVD risk (Keech et al., 2005; Accord Study Group et al., 2010)	IIb	C

TG: triglycerides; ASCVD: atherosclerotic cardiovascular disease; IPE: icosapent ethyl.